The Health Resources & Services Administration has told Johnson & Johnson it cannot use a rebate model to replace upfront discounts in its 340B drug pricing program, according to the American Hospital Association.
Category: Reimbursement, Finance, Population and Public Health, Social determinants of health, Legislation, Compliance, Medicare and Medicaid, Regulation, Business, Care, Public Policy
